SUPPLEMENTARY TABLE 2. PROGNOSTIC FACTORS FOR PFS AND OS IN UNIVARIATE ANALYSIS
Preinfusion parameters
PFS OS
HR 95% CI p∞ HR 95% CI p∞
Age, years
> 65 (v ≤ 65) 0.89 0.45-1.74 0.74 1.11 0.46-2.66 0.8
Sex
Male (v female) 1.23 0.62-2.44 0.54 1.22 0.53-2.82 0.63
ECOG
≥ 2 (v < 2) 1.18 0.58-2.42 0.63 1.34 0.58-3.09 0.48
B symptoms
Yes (v no) 2.17 0.83-5.66 0.11 2.74 0.77-9.69 0.11
Stage
III-IV (v I-II) 1.35 0.59-3.11 0.37 1.58 0.57-4.36 0.36
Number of lines before leukapheresis
≥ 4 (v < 4) 1.99 1.0-3.95 0.049 1.12 0.45-2.78 0.8
Lymphoma subtype DLBCL (v tr-iNHL) PMBCL (v tr-iNHL)
1.31 0.99
0.59-2.92 0.21-4.68
0.5 0.99
1.31 2.76
0.43-4.0 0.5-15.3
0.62 0.24 Expressor status
Double expressor (v no-DE) 1.71 0.75-3.88 0.2 4.85 1.31-17.99 0.0018
Translocation status
DH/TH (v no DH/TH) 0.70 0.20-2.45 0.58 1.43 0.36-5.50 0.6
Cell of origin
Germinal centre (v non-GC) 1.25 0.63-2.45 0.51 1.3 0.54-3.09 0.55
Bulky mass, cm
> 10 (v ≤ 10) 2.3 0.99-5.55 0.050 3.72 1.38-10.03 0.0090
LDH
>UNL (v ≤UNL) 1.94 0.8-4.68 0.13 1.21 0.44-3.27 0.7
C reactive protein, mg/mL
> 30 (v ≤ 30) 2.29 1.14-4.59 0.019 2.11 0.92-4.88 0.077
Refractory
∞Bold font indicates statistical significance
Abbreviations: ECOG, Eastern Cooperative Oncology Group; DLBCL, diffuse large B-cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; tr-iNHL, transformed indolent non-Hodgkin lymphoma; LDH, lactate dehydrogenase; UNL, upper normal limit; GC, germinal centre; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; DE, double expressor; DH, double hit; TH, triple hit; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome.
Primary (v no) 1.03 0.51-2.08 0.91 1.47 0.58-3.74 0.41
Secondary (v no) 1.49 0.45-4.9 0.52 3.27 0.44-24.45 0.24
Prior autologous transplant
Yes (v no) 1.29 0.63-2.63 0.47 0.99 0.39-2.48 0.98
CAR T-cell type
tisa-cel (v axi-cel) 1.62 0.81-3.21 0.16 1.58 0.6-4.14 0.89
Postinfusion parameters
PFS OS
HR 95% CI p ∞ HR 95% CI p ∞
CRS
all grades (v no) 0.85 0.31-2.30 0.75 6.68 0.85-52.10 0.069
CRS
≥ 3 (v < 3) 0.62 0.084-4.64 0.64 2.20 0.50-9.57 0.29
ICANS
all grades (v no) 0.78 0.31-1.96 0.60 1.052 0.37-2.92 0.92
ICANS
≥ 3 (v < 3) 1.08 0.32-3.65 0.89 1.76 0.51-6.70 0.36
Tocilizumab use
yes (v no) 0.50 0.224-1.15 0.10 1.55 0.61-3.88 0.35
Dexamethasone use
yes (v no) 0.64 0.26-1.54 0.32 1.09 0.43-2.70 0.85
Intensive care unit transfer
yes (v no) 1.00 0.38-2.60 0.44 1.36 0.45-4.09 0.58
